Tesamorelin

Tesamorelin is an FDA-approved synthetic growth hormone-releasing hormone (GHRH) analog — a 44-amino acid peptide with a trans-3-hexenoic acid modification that extends its half-life and stability. Originally approved for HIV-associated lipodystrophy, it's unique because it selectively reduces visceral adipose tissue (deep abdominal fat around organs) while preserving subcutaneous fat. This targeted approach makes it distinct from other GH therapies that reduce fat indiscriminately.

MECHANISM OF ACTION

Tesamorelin binds GHRH receptors on pituitary somatotroph cells and stimulates pulsatile growth hormone release — mimicking the body's natural GH rhythm rather than causing continuous elevation. The trans-3-hexenoic acid modification at the N-terminus increases stability and bioavailability compared to native GHRH.

This pulsatile pattern is critical: it preserves natural GH signaling dynamics and avoids receptor desensitization that occurs with continuous GH exposure.

POTENTIAL BENEFITS

• Selective visceral fat reduction (the metabolically harmful fat around organs)

• Improved triglyceride and cholesterol profiles

• Lean muscle mass preservation during fat loss

• Enhanced metabolic function and insulin sensitivity

• Cardiovascular risk reduction through metabolic improvements

• Anti-inflammatory effects (reduced VEGFA, TGFB1, CSF1)

• Improved energy, sleep quality, and recovery

• Body composition remodeling with visible waist circumference reduction

• FDA-approved with extensive clinical validation
  

WHY IT'S BEING RESEARCHED

Tesamorelin addresses a critical gap: most GH therapies reduce all fat indiscriminately, but visceral fat is metabolically toxic — it drives insulin resistance, inflammation, and cardiovascular disease.

Tesamorelin's selective targeting of visceral fat while sparing subcutaneous fat is unique. A 2025 meta-analysis confirmed cardiovascular risk reduction through improved metabolic parameters. A 2021 study showed anti-inflammatory effects beyond simple fat loss, with reduced inflammatory markers (VEGFA, TGFB1, CSF1).

The pulsatile GH release pattern preserves natural physiology better than continuous GH elevation, reducing acromegaly risk.

INTERESTING FACTS

• Only GHRH analog with selective visceral fat targeting — other GH therapies reduce all fat

• 44 amino acids with trans-3-hexenoic acid modification for extended half-life

• FDA-approved for HIV lipodystrophy; approved in 35+ countries

• Pulsatile GH release mimics natural rhythm — avoids receptor desensitization

• Peak effects at 12–26 weeks; continuous treatment (effects reverse upon discontinuation)

• 3.3-fold increased diabetes risk — requires monthly blood glucose and IGF-1 monitoring

• 47% of users exceed normal IGF-1 range at 26 weeks

• Evening injection preferred to align with natural GH circadian rhythm

  
  

STACKING

Ipamorelin

Synergistic GH stimulation. Requires careful monitoring of IGF-1 and blood glucose. Start at reduced doses and titrate slowly.

Both elevate GH; combined effect is additive.

Sermorelin

Dose-dependent compatibility. Low-dose Sermorelin may complement; higher doses risk excessive GH elevation.

Monitor IGF-1 monthly.

Avoid

CJC-1295 or CJC-1295 DAC

Both are GHRH analogs that bind the same receptor.

Stacking causes receptor saturation and desensitization without amplifying GH response. Redundant mechanism.

Monitor Closely

Insulin or Glucose-Lowering Agents

Tesamorelin increases diabetes risk 3.3-fold. Blood glucose elevation is common.

Adjust insulin doses and monitor fasting glucose and HbA1c monthly.

Corticosteroids

May blunt GH response.

Discuss timing and necessity with healthcare provider.

Safety Note

Tesamorelin requires monthly IGF-1 and fasting glucose monitoring. Diabetes risk is significant; baseline metabolic screening is essential before starting.

RESEARCH PURPOSES ONLY

NOT AVAILABLE FOR HUMAN CONSUMPTION